Fig. 3From: Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experienceThe cost-effectiveness acceptability curves for T-DXd strategy compared to T-DM1 strategyBack to article page